Simultaneous quantification of apolipoproteins A-I, E, and J in human plasma by LC-MS/MS for clinical application to diabetes mellitus complicated with cardiovascular disease-Reference-Cited by-同舟云学术

Simultaneous quantification of apolipoproteins A-I, E, and J in human plasma by LC-MS/MS for clinical application to diabetes mellitus complicated with cardiovascular disease

Published:2022 Issue:26 Volume:12 Page:16763-16771
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Li Pengfei¹^ORCID,Cong Yuting²,Zhang Wen¹,Wang Lefeng³,Ren Lulu¹,Li Xin³,Yang Song¹,Zhang Zhiyong³,Li Guoqing²,Liu Lihong¹

Affiliation:

1. Pharmacy Department of Beijing Chao-Yang Hospital, Capital Medical University, No. 8 Gongti South Road, Chaoyang District, Beijing, China

2. Shanghai AB Sciex Analytical Instrument Trading Co. Ltd, 518 North Fuquan Road, Changning District, Shanghai, China

3. Heart Center of Beijing Chao-Yang Hospital, Capital Medical University, No. 8 Gongti South Road, Chaoyang District, Beijing, China

Abstract

Simultaneous quantification of apolipoproteins A-I, E, and J in human plasma by LC-MS/MS.

Funder

National Natural Science Foundation of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/RA/D2RA02840A

Reference27 articles.

1. Apolipoprotein status in type 2 diabetes mellitus and its complications

2. Apolipoprotein A-I and B Levels and the Risk of Ischemic Heart Disease During a Five-Year Follow-up of Men in the Que´bec Cardiovascular Study

3. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence

4. The HDL cholesterol/apolipoprotein A-I ratio

5. Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus